未标记和14C标记的吲哚洛尔在尿毒症中的药代动力学。 - Suppr

Suppr

超能文献

Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia.

作者信息

Ohnhaus E E, Nüesch E, Meier J, Kalberer F

出版信息

Eur J Clin Pharmacol. 1974;7(1):25-9. doi: 10.1007/BF00614386.

DOI:10.1007/BF00614386

PMID:4853607

Abstract

摘要

相似文献

Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia.未标记和14C标记的吲哚洛尔在尿毒症中的药代动力学。

Eur J Clin Pharmacol. 1974;7(1):25-9. doi: 10.1007/BF00614386.

The pharmacokinetics of unchanged pindolol in patients with impaired renal function.肾功能受损患者中未代谢的吲哚洛尔的药代动力学。

Br J Pharmacol. 1973 Mar;47(3):620P-621P.

Pharmacokinetics of pindolol in man.吲哚洛尔在人体中的药代动力学。

Eur J Clin Pharmacol. 1974;7(1):17-24. doi: 10.1007/BF00614385.

beta-Adrenoceptor blocking effects and pharmacokinetics of pindolol. A study in hypertensive Africans.吲哚洛尔的β-肾上腺素受体阻断作用及药代动力学。一项针对非洲高血压患者的研究。

Eur J Clin Pharmacol. 1979 Jun 12;15(5):299-304. doi: 10.1007/BF00558431.

Pharmacokinetics of practolol in renal failure.心得宁在肾衰竭患者中的药代动力学

Eur J Clin Pharmacol. 1974 Jul 26;7(4):249-52. doi: 10.1007/BF00560339.

Metabolism of pindolol in patients with renal failure.肾衰竭患者中吲哚洛尔的代谢

Eur J Clin Pharmacol. 1982;22(5):423-8. doi: 10.1007/BF00542547.

Pharmacokinetics of furosemide in normal subjects and functionally anephric patients.速尿在正常受试者和功能性无肾患者中的药代动力学。

Clin Pharmacol Ther. 1974 Jun;15(6):588-96. doi: 10.1002/cpt1974156588.

Metabolism of nitrogen and heavy nitrogen in uraemia.尿毒症中氮及重氮的代谢

Minerva Nefrol. 1969 Jan-Feb;16(1):1-14.

Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.苯妥英在尿毒症患者中的动力学：血浆蛋白结合降低的后果

Eur J Clin Pharmacol. 1974;7(1):31-7. doi: 10.1007/BF00614387.

Simultaneous tubular excretion and reabsorption of pindolol in man.人体中吲哚洛尔的同时肾小管排泄与重吸收

Eur J Clin Pharmacol. 1981;21(1):65-72. doi: 10.1007/BF00609590.

引用本文的文献

Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.全身性高血压中的β-肾上腺素能阻滞剂：与现行指南相关的药代动力学考量

Clin Pharmacokinet. 2002;41(7):505-16. doi: 10.2165/00003088-200241070-00004.

Pharmacokinetics of acebutolol in patients with all grades of renal failure.醋丁洛尔在各程度肾衰竭患者中的药代动力学

Eur J Clin Pharmacol. 1980 May;17(5):339-48. doi: 10.1007/BF00558446.

Metabolism of pindolol in patients with renal failure.肾衰竭患者中吲哚洛尔的代谢

Eur J Clin Pharmacol. 1982;22(5):423-8. doi: 10.1007/BF00542547.

Elimination of pindolol in liver disease.肝病患者中吲哚洛尔的消除情况。

Eur J Clin Pharmacol. 1982;22(3):247-51. doi: 10.1007/BF00545223.

A standard approach to compiling clinical pharmacokinetic data.一种汇编临床药代动力学数据的标准方法。

J Pharmacokinet Biopharm. 1981 Feb;9(1):59-127. doi: 10.1007/BF01059343.

Pharmacokinetics of mepindolol in patients with chronic renal failure.美吲哚洛尔在慢性肾衰竭患者中的药代动力学

Eur J Clin Pharmacol. 1984;27(4):429-33. doi: 10.1007/BF00549590.

Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.药物动力学特性的差异：对肾衰竭患者选用特定药物的意义，特别强调抗生素和β-肾上腺素能受体阻滞剂。

Clin Pharmacokinet. 1980 Sep-Oct;5(5):441-64. doi: 10.2165/00003088-198005050-00003.

Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.美托洛尔在肾功能受损患者中的药代动力学和药效学特性。

Clin Pharmacokinet. 1980 Mar-Apr;5(2):169-80. doi: 10.2165/00003088-198005020-00004.

Contrasts between pindolol and propranolol concentration-response relationships.吲哚洛尔与普萘洛尔浓度-反应关系的对比。

Br J Clin Pharmacol. 1985 Oct;20(4):417-20. doi: 10.1111/j.1365-2125.1985.tb05088.x.

Stereoselective renal clearance of pindolol in humans.吲哚洛尔在人体中的立体选择性肾脏清除率。

J Clin Invest. 1985 Nov;76(5):1720-6. doi: 10.1172/JCI112161.

本文引用的文献

The pathologic physiology of chronic Bright's disease. An exposition of the "intact nephron hypothesis".慢性布赖特氏病的病理生理学。“完整肾单位假说”阐释。

Am J Med. 1960 Jan;28:77-98. doi: 10.1016/0002-9343(60)90225-4.

[Excretion of doxycycline and the effect of hemodialysis in anurid].

Schweiz Med Wochenschr. 1971 Jan 30;101(4):123-7.

Multiple dose kinetics and drug dosage in patients with kidney disease.肾病患者的多剂量动力学与药物剂量

Acta Pharmacol Toxicol (Copenh). 1971;29 Suppl 3:211-24. doi: 10.1111/j.1600-0773.1971.tb03301.x.

Pharmacodynamics of propranolol in renal failure.普萘洛尔在肾衰竭中的药效学。

Br Med J. 1972 May 20;2(5811):434-6. doi: 10.1136/bmj.2.5811.434.

[Serum creatinine determination without protein precipitation].[无需蛋白质沉淀的血清肌酐测定]

Clin Chim Acta. 1972 Mar;37:193-7. doi: 10.1016/0009-8981(72)90432-9.

[Pharmacokinetics of indomethacin in patients with kidney lesions].

Int J Clin Pharmacol. 1972 Aug;6(3):237-42.

A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.一种荧光法测定血浆和尿液中β受体阻滞剂4-(2-羟基-3-异丙氨基丙氧基)-吲哚(LB46)的方法。

Experientia. 1969 Aug 15;25(8):802-3. doi: 10.1007/BF01897885.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验